common.study.topics.clinical

Hormonal Contraception on HIV Acquisition and Transmission

common.study.values.description

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

This is a prospective cohort study focusing on HIV negative women. The investigators want to learn how the following types of contraceptive methods: Depot medroxyprogesterone acetate (DMPA), Etonogestrel impant (Eng-Implant), Levonorgestrel intrauterine device (Lng-IUD) and the ParaGardAR T 380A Intrauterine Copper Contraceptive impacts the vaginal immune environment.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Depot medroxyprogesterone acetate (DMPA)

DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.

Device - Etonogestrel implant (Eng-Implant)

A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.

Device - Levonorgestrel intrauterine device (Lng-IUD)

A standard Mirena IUD will be placed at study week 3 by a trained clinician.

Device - ParaGard® T 380A Intrauterine Copper Contraceptive

A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

common.study.values.clinical-trial-id

NCT02357368

participant.views.study.view.id

QbYQOb